# Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children

> **NCT03868852** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Xinhua Hospital, Shanghai Jiao Tong University School of Medicine** · enrollment: 48 (estimated)

## Conditions studied

- Childhood Rhabdomyosarcoma

## Interventions

- **DRUG:** Apatinib mesylate tablets
- **RADIATION:** Three-dimensional conformal intensity modulation

## Key facts

- **NCT ID:** NCT03868852
- **Lead sponsor:** Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-01-01
- **Primary completion:** 2020-04-01
- **Final completion:** 2020-04-01
- **Target enrollment:** 48 (ESTIMATED)
- **Last updated:** 2019-03-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03868852

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03868852, "Efficacy and Safety of Radiotherapy Combined With Apatinib Mesylate in the Treatment of Rhabdomyosarcoma in Children". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT03868852. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*